{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:58:57Z","timestamp":1794002337132,"version":"4.8.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"Importance<\/jats:title>The role of stereotactic ablative radiotherapy (SABR) for gynecologic malignant tumors has yet to be clearly defined despite recent clinical uptake.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the outcomes of SABR in patients with oligometastatic and oligoprogressive gynecologic cancers.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this retrospective pooled analysis, patients with oligometastatic and oligoprogressive gynecologic cancers receiving SABR at 5 institutions from Canada and the US were studied. Data were collected from January 2011 to December 2020, and data were analyzed from January to December 2023.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Stereotactic ablative radiotherapy.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Cumulative incidence of local and distant recurrence, chemotherapy-free survival (CFS), and overall survival (OS) probabilities after SABR were calculated using Kaplan-Meier methods. Univariable and multivariable analysis was conducted using Cox regression methods.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 215 patients with 320 lesions meeting criteria were included in the analysis; the median (range) age at primary diagnosis was 59 (23-86) years. The median (range) follow-up from SABR was 18.5 (0.1-124.5) months. The primary site included the endometrium (n\u2009=\u2009107), ovary (n\u2009=\u200964), cervix (n\u2009=\u200930), and vulva or vagina (n\u2009=\u200914). Local cumulative incidence of recurrence was 13.7% (95% CI, 9.4-18.9) and 18.5% (95% CI, 13.2-24.5) at 1 and 5 years, respectively. Distant cumulative incidence of recurrence was 48.5% (95% CI, 41.4-55.1) and 73.1% (95% CI, 66.0-79.0) at 1 and 5 years, respectively. OS was 75.7% (95% CI, 69.2-81.1) and 33.1% (95% CI, 25.3-41.1) at 1 and 5 years, respectively. The median CFS was 21.7 months (95% CI, 15.4-29.9). On multivariable analysis, local recurrence was significantly associated with nodal metastasis, lesion size, biologically effective dose, treatment indication, institution, and primary disease type. Distant progression-free survival was associated with nodal targets and lesion size. OS and CFS were significantly associated with lesion size.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this study, SABR appeared to have excellent local control with minimal toxic effects in this large patient group, and certain patients may achieve durable distant control and OS as well. It may be possible to delay time to chemotherapy in select patient subtypes and therefore reduce associated toxic effects. Prospective multicenter trials will be critical to establish which characteristics procure the greatest benefit from SABR use and to define the ideal time to implement SABR with other oncologic treatments.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.1796","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:03:15Z","timestamp":1718290995000},"page":"941","source":"Crossref","is-referenced-by-count":21,"title":["Stereotactic Ablative Radiotherapy for Gynecological Oligometastatic and Oligoprogessive Tumors"],"prefix":"10.1001","volume":"10","author":[{"given":"Elysia K.","family":"Donovan","sequence":"first","affiliation":[{"name":"Department of Oncology, Division of Radiation Oncology, Escarpment Cancer Research Institute, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Beriwal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Keller","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Nwachukwu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Mantz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Genesis Care, Fort Myers, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Pond","sequence":"additional","affiliation":[{"name":"Escarpment Cancer Research Institute, Department of Oncology, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Schnarr","sequence":"additional","affiliation":[{"name":"Department of Oncology, Division of Radiation Oncology, Escarpment Cancer Research Institute, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Swaminath","sequence":"additional","affiliation":[{"name":"Department of Oncology, Division of Radiation Oncology, Escarpment Cancer Research Institute, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Albuquerque","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10185","key":"coi240020r1","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"coi240020r2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ijrobp.2017.02.093","article-title":"Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter.","volume":"98","author":"Helou","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi240020r3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.lungcan.2018.08.005","article-title":"Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: delaying the need to start or change systemic therapy?","volume":"124","author":"Merino Lara","year":"2018","journal-title":"Lung Cancer"},{"key":"coi240020r4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.radonc.2019.08.018","article-title":"Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: dose and site of metastases matter.","volume":"142","author":"Thompson","year":"2020","journal-title":"Radiother Oncol"},{"issue":"1","key":"coi240020r5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13014-020-1469-8","article-title":"Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy.","volume":"15","author":"Leung","year":"2020","journal-title":"Radiat Oncol"},{"issue":"2","key":"coi240020r6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ygyno.2020.08.010","article-title":"Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: a systematic review.","volume":"159","author":"Yegya-Raman","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"7","key":"coi240020r7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11864-020-00748-6","article-title":"Stereotactic ablative radiotherapy for recurrent or metastatic gynecological cancer: extending lives?","volume":"21","author":"Zhang","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"coi240020r8","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 Study): a collaboration of MITO, AIRO GYN, and MaNGO groups.","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"coi240020r9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday.","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi240020r10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fonc.2012.00181","article-title":"Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies.","volume":"2","author":"Kunos","year":"2012","journal-title":"Front Oncol"},{"issue":"9","key":"coi240020r11","first-page":"5103","article-title":"Stereotactic body radiotherapy for recurrent or oligometastatic uterine cervix cancer: a cooperative study of the Korean Radiation Oncology Group (KROG 14-11).","volume":"35","author":"Park","year":"2015","journal-title":"Anticancer Res"},{"issue":"3","key":"coi240020r12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ygyno.2020.10.001","article-title":"Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.","volume":"159","author":"Reshko","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"2","key":"coi240020r13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/IGC.0000000000000869","article-title":"Clinical outcomes for stereotactic ablative radiotherapy in oligometastatic and oligoprogressive gynecological malignancies.","volume":"27","author":"Mesko","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"coi240020r14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.572564","article-title":"Stereotactic body radiation therapy: a versatile, well-tolerated, and effective treatment option for extracranial metastases from primary ovarian and uterine cancer.","volume":"10","author":"Aghdam","year":"2020","journal-title":"Front Oncol"},{"key":"coi240020r15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fonc.2016.00249","article-title":"Survival and control prognosticators of recurrent gynecological malignancies of the pelvis and para-aortic region treated with stereotactic body radiation therapy.","volume":"6","author":"Hasan","year":"2016","journal-title":"Front Oncol"},{"issue":"1","key":"coi240020r16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13014-020-01564-w","article-title":"Stereotactic body radiation therapy in the treatment of ovarian cancer.","volume":"15","author":"Kowalchuk","year":"2020","journal-title":"Radiat Oncol"},{"issue":"5","key":"coi240020r17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3109\/07357907.2015.1019678","article-title":"Stereotactic body radiotherapy for oligometastases confined to the para-aortic region: clinical outcomes and the significance of radiotherapy field and dose.","volume":"33","author":"Seo","year":"2015","journal-title":"Cancer Invest"},{"issue":"6","key":"coi240020r18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clon.2017.01.009","article-title":"The role of stereotactic ablative body radiotherapy in gynaecological cancers: a systematic review.","volume":"29","author":"Mendez","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"12","key":"coi240020r19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"coi240020r21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma.","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"coi240020r22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ygyno.2019.03.255","article-title":"Immunotherapy and radiation combinatorial trials in gynecologic cancer: a potential synergy?","volume":"154","author":"Lee","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"5","key":"coi240020r23","first-page":"331","article-title":"Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.","volume":"29","author":"Sharabi","year":"2015","journal-title":"Oncology (Williston Park)"},{"key":"coi240020r24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctrv.2016.11.003","article-title":"The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: what do we know and where are we going?","volume":"52","author":"Hong","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"coi240020r25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fonc.2015.00126","article-title":"Phase I trial of carboplatin and gemcitabine chemotherapy and stereotactic ablative radiosurgery for the palliative treatment of persistent or recurrent gynecologic cancer.","volume":"5","author":"Kunos","year":"2015","journal-title":"Front Oncol"},{"issue":"1","key":"coi240020r26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ygyno.2017.10.017","article-title":"Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer.","volume":"148","author":"Ning","year":"2018","journal-title":"Gynecol Oncol"},{"key":"coi240020r20","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Accessed May 1, 2022. https:\/\/academy.myeloma.org.uk\/wp-content\/uploads\/2015\/04\/CTCAE_v5.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2820082\/jamaoncology_donovan_2024_oi_240020_1722368502.43229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T15:00:28Z","timestamp":1722524428000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2820082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.1796","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}